中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
Prognostic biomarker discovery based on proteome landscape of Chinese lung adenocarcinoma

文献类型：期刊论文

作者Huang, Yuqi4,5; Ma, Sheng3; Xu, Jun-Yu1,5; Qian, Kun2; Wang, Yaru3; Zhang, Yi2; Tan, Minjia1,4,5; Xiao, Ting3
刊名CLINICAL PROTEOMICS
出版日期2024-12-01
卷号21期号:1页码:11
ISSN号1542-6416
关键词Lung adenocarcinoma Proteome Benign lung disease cases Solid pathological subtype Prognostic biomarker
DOI10.1186/s12014-023-09449-2
通讯作者Xu, Jun-Yu(jyxu@simm.ac.cn) ; Zhang, Yi(steven9130@sina.com) ; Tan, Minjia(mjtan@simm.ac.cn) ; Xiao, Ting(xiaot@cicams.ac.cn)
英文摘要Despite recent innovations in imaging and genomic screening promotes advance in diagnosis and treatment of lung adenocarcinoma (LUAD), there remains high mortality of LUAD and insufficient understanding of LUAD biology. Our previous study performed an integrative multi-omic analysis of LUAD, filling the gap between genomic alterations and their biological proteome effects. However, more detailed molecular characterization and biomarker resources at proteome level still need to be uncovered. In this study, a quantitative proteomic experiment of patient-derived benign lung disease samples was carried out. After that, we integrated the proteomic data with previous dataset of 103 paired LUAD samples. We depicted the proteomic differences between non-cancerous and tumor samples and among diverse pathological subtypes. We also found that up-regulated mitophagy was a significant characteristic of early-stage LUAD. Additionally, our integrative analysis filtered out 75 potential prognostic biomarkers and validated two of them in an independent LUAD serum cohort. This study provided insights for improved understanding proteome abnormalities of LUAD and the novel prognostic biomarker discovery offered an opportunity for LUAD precise management.
WOS关键词MIGRATION INHIBITORY FACTOR ; RESPIRATORY SOCIETY CLASSIFICATION ; INTERNATIONAL ASSOCIATION ; CANCER STATISTICS ; SERUM ; MITOCHONDRIA ; CELLS ; TFEB ; EXPRESSION ; MANAGEMENT
资助项目Shanghai Rising-Star Program
WOS研究方向Biochemistry & Molecular Biology
语种英语
出版者BMC
WOS记录号WOS:001137103900001
源URL[http://119.78.100.183/handle/2S10ELR8/308505]  
专题中国科学院上海药物研究所
通讯作者Xu, Jun-Yu; Zhang, Yi; Tan, Minjia; Xiao, Ting
作者单位1.Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan 528400, Guangdong, Peoples R China
2.Capital Med Univ, Xuanwu Hosp, Dept Thorac Surg, Beijing 100053, Peoples R China
3.Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, State Key Lab Mol Oncol,Dept Etiol & Carcinogenesi, Beijing 100021, Peoples R China
4.Univ Chinese Acad Sci, Beijing, Peoples R China
5.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
推荐引用方式
GB/T 7714		 Huang, Yuqi,Ma, Sheng,Xu, Jun-Yu,et al. Prognostic biomarker discovery based on proteome landscape of Chinese lung adenocarcinoma[J]. CLINICAL PROTEOMICS,2024,21(1):11.
APA Huang, Yuqi.,Ma, Sheng.,Xu, Jun-Yu.,Qian, Kun.,Wang, Yaru.,...&Xiao, Ting.(2024).Prognostic biomarker discovery based on proteome landscape of Chinese lung adenocarcinoma.CLINICAL PROTEOMICS,21(1),11.
MLA Huang, Yuqi,et al."Prognostic biomarker discovery based on proteome landscape of Chinese lung adenocarcinoma".CLINICAL PROTEOMICS 21.1(2024):11.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。